查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1986482

製药连续生产市场报告：按治疗领域、剂型、应用、最终用户和地区划分（2026-2034 年）

Pharmaceutical Continuous Manufacturing Market Report by Therapeutics Type, Formulation, Application, End User, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 143 Pages | 商品交期: 2-3个工作天内

价格

2025年，全球製药连续生产市场规模达16亿美元。展望未来，IMARC集团预测，到2034年，该市场规模将达到37亿美元，2026年至2034年的复合年增长率（CAGR）为9.24%。北美凭藉其先进的技术基础设施，在该市场中展现出明显的优势。此外，日益增强的健康意识和活性化的研发投入也推动了市场成长。同时，对高效製药生产系统的需求不断增长，也对市场产生了积极影响。

製药连续生产市场正迅速发展，全球製药业正不断采用新技术来提高效率、品质和扩充性。永续性正成为製药生产的关键考量因素，而连续生产系统与环保实践相契合。能源消耗正在降低，原料利用效率正在提高，废弃物产生量也正在减少。企业正在实施环保工艺，碳足迹正在缩小。连续生产支持製药业对永续的承诺。随着环境法规日益严格，製造商正在调整其业务运营，以符合全球永续性目标。这一趋势进一步提升了连续生产流程的吸引力。

製药连续生产市场的发展趋势：

慢性病增多

全球慢性病（如糖尿病、心血管疾病、癌症和呼吸系统疾病）发生率的不断上升，正推动製药业采用连续生产技术。医疗系统不断调整以应对日益增长的患者数量，製药公司也相应地扩大产能。传统的间歇式生产难以满足救命药物的持续需求，而连续生产则提供了更快、更经济、更稳定的生产解决方案。这项技术能够实现药品不间断的生产，确保供应能够跟上不断增长的治疗需求。各公司也正致力于解决供不应求，提高药品的可及性，特别是那些用于长期治疗的基本药物。根据国际糖尿病联盟（IDF）最新发布的《糖尿病地图集（2025）》，20至79岁的成年人中，11.1%（九分之一）患有糖尿病，超过40%的人对此毫不知情。随着慢性病在已开发经济体和新兴经济体的盛行率不断上升，对经济高效且扩充性的生产方式的需求也日益增长。连续生产透过稳定的品质和供应满足了这一需求，确保患者始终能够不间断地获得必需药物。

技术创新与发展

随着製药公司不断将自动化、人工智慧、数位双胞胎和预测分析等技术融入生产流程，科技的快速发展正推动连续生产模式的普及。先进的过程控制系统能够实现即时追踪，机器学习演算法则可预测潜在偏差，从而最大限度地提高效率。这些进步带来了更稳定的产品品质、更少的停机时间和更低的变异性。模组化系统结构提供了柔软性，使工厂无需大规模重组即可适应多种规格的药品。企业也在投资数位化平台，透过端到端的可追溯性，实现整个生产週期的完全透明。结合工业4.0技术，製药生产正变得更加智慧、敏捷和有效率。这些技术正将连续生产确立为面向未来的製药生产的支柱，帮助企业在满足全球对价格合理、可靠且高品质的药品日益增长的需求的同时，保持竞争力。根据IMARC集团预测，到2033年，全球工业4.0市场规模预计将达到5,705亿美元。

监管机构的支持与鼓励

监管机构正通过支持性指南、核准和框架，日益鼓励连续生产。美国食品药物管理局(FDA) 透过监管柔软性来推动创新，而欧洲药品管理局 (EMA) 和日本药品和医疗设备管理局 (PMDA) 则致力于与全球标准接轨。这些机构正在为连续生产技术的快速普及铺平道路，企业也积极响应，申请相关技术的核准。监管机构透过提供合规指导，鼓励製药公司采用即时品质监控、流程分析技术 (PAT) 和先进控制系统。这种支援降低了不确定性，加速了技术的普及，并增强了业界的信心。随着更多核准的通过，法规环境对连续生产系统的信心也不断增强。这种积极的态度正在推动小分子药物、生物製药和个人化医疗领域的应用，整个产业正逐步在全球范围内向更广泛地整合连续生产模式转型。 2024 年，美国食品药物管理局(FDA) 宣布，将于 2024 年 1 月 2 日至 3 月 1 日接受 START试验计画的申请，该计画旨在加速罕见疾病治疗药物的研发。当研发项目达到与申办方协议中规定的关键监管里程碑时，例如启动主要临床核准阶段或达到上市前阶段（生技药品核准前或新药认证前会议），该试点项目的申办即被视为完成。

推动製药连续生产市场成长要素：

降低成本和营运效益

由于其巨大的成本效益潜力和营运优势，製药业正逐步采用连续生产（MCM）。传统的批次生产需要大量的空间、人力和较长的前置作业时间，而连续生产系统则能降低能耗、原料消耗和废弃物产生。透过简化製程，企业能够降低生产成本，并在更少的生产週期内实现更高的产量。连续生产系统还能加速规模化生产，使製造商能够更快地从研发阶段过渡到大规模生产。在全球竞争日益激烈、药品价格压力不断增大的环境下，这些优势尤其重要。此外，连续生产还能透过缩小生产空间来降低基础设施成本。透过维持产品品质的稳定性并最大限度地减少生产缺陷，企业可以避免代价高昂的延误和召回。在一个力求在不牺牲安全性和品质的前提下，平衡药品价格、合规性和病患可及性的产业中，这些营运效率的提升正成为推动产业发展的重要动力。

对生物製药和先进疗法的需求日益增长

随着对生物製药、生物相似药以及细胞和基因疗法等先进治疗方法的需求快速增长，製药业正日益转向连续生产。传统的间歇式生产流程已无法满足这些治疗方法的多样化需求，而连续生产製程则能提供更高的一致性、效率和扩充性。企业正在采用连续上游工程（例如灌註生物反应器）和连续下游製程（例如层析法），以确保产品品质。这些方法缩短了生产週期，并加速了关键治疗方法的上市。生物製药产业也要求精确控制变异性，而连续系统透过实现即时监测和先进的控制机制来满足这一需求。随着全球对个人化和复杂治疗方法的需求不断增长，连续生产在满足患者需求方面发挥主导作用。这种转变使製药业能够有效地应对其最重要的驱动因素之一。

人们越来越关注供应链韧性

在全球供应链动盪之后，製药公司越来越重视供应链韧性，连续生产模式也因此得到日益广泛的应用。传统的大量生产通常依赖漫长的供应链和集中的製造地，因此极易出现延误和供不应求。相较之下，连续生产模式能够实现以本地为中心、分散化且灵活的生产模式，从而减少对复杂物流链的依赖。企业正在靠近患者的地方建立小规模模组化工厂，以确保患者能够及时获得药物。这种策略降低了紧急情况下供应链中断的风险，并增强了应对意外需求激增的能力。透过提高供应链的柔软性，连续生产使製药公司能够更快地响应市场变化。在对供应链韧性日益重视的背景下，企业逐渐意识到更安全、更有效率、更永续的生产方案所蕴含的策略优势，进而推动了连续生产模式的普及应用。

目录

第一章：序言

第二章：调查方法

  • 调查目的
  • 相关利益者
  • 数据来源
    • 主要讯息
    • 次要讯息
  • 市场估值
    • 自下而上的方法
    • 自上而下的方法
  • 调查方法

第三章执行摘要

第四章：引言

第五章：全球製药连续生产市场

  • 市场概览
  • 市场表现
  • 新冠疫情的影响
  • 市场预测

第六章 市场区隔：依治疗区域划分

  • 聚合物化合物
  • 低分子化合物

第七章 市场区隔：依剂型划分

  • 固态剂型
  • 液体和半固态製剂

第八章 市场区隔：依应用领域划分

  • 最终药品生产
  • 原料药（API）生产

第九章 市场区隔：依最终用户划分

  • 製药公司
  • 契约製造组织
  • 其他的

第十章 市场区隔：依地区划分

  • 北美洲
    • 我们
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第十一章 SWOT 分析

第十二章：价值链分析

第十三章：波特五力分析

第十四章：价格分析

第十五章 竞争格局

  • 市场结构
  • 主要企业
  • 主要企业简介
    • Baker Perkins
    • Coperion GmbH（Hillenbrand Inc.）
    • Eli Lilly and Company
    • GEA Group Aktiengesellschaft
    • Glatt GmbH
    • Korsch AG
    • Novartis AG
    • Siemens
    • SK biotek
    • Thermo Fisher Scientific Inc.
    • Viatris Inc.
Product Code: SR112026A5935

The global pharmaceutical continuous manufacturing market size reached USD 1.6 Billion in 2025 . Looking forward, IMARC Group expects the market to reach USD 3.7 Billion by 2034 , exhibiting a growth rate (CAGR) of 9.24% during 2026-2034 . North America exhibits a clear dominance in the market due to its advanced technological infrastructure. Moreover, rising health concerns and increasing research and development (R&D) activities are propelling the market growth. Additionally, rising demand for effective medicine production systems is positively influencing the market.

The pharmaceutical continuous manufacturing market is experiencing rapid evolution, and the global industry is increasingly adopting new technologies to improve efficiency, quality, and scalability. Sustainability is becoming a critical consideration in pharmaceutical manufacturing, and continuous production systems are aligning with green initiatives. Energy consumption is decreasing, raw material usage is becoming more efficient, and waste generation is reducing. Companies are implementing environmentally friendly processes, and carbon footprints are shrinking. Continuous manufacturing is supporting the pharmaceutical industry's commitment to sustainable development. As environmental regulations are tightening, manufacturers are aligning operations with global sustainability goals. This trend is reinforcing the attractiveness of continuous processes.

PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET TRENDS:

Growing Prevalence of Chronic Disease

The global increasing incidence of chronic diseases like diabetes, cardiovascular disease, cancer, and respiratory disease is propelling the adoption of continuous manufacturing by the pharmaceutical sector. Healthcare systems are dealing with ever-increasing numbers of patients day by day, and pharma companies are reacting accordingly by increasing production capacity. Legacy batch operations are having a hard time keeping pace with unrelenting demand for life-saving pharmaceuticals, whereas continuous production is providing quicker, more economical, and more consistent solutions for manufacturing. In permitting unbroken output of medicines, this technology is guaranteeing that supply is meeting rising therapeutic demand. Firms are also emphasizing shortening shortages and enhancing availability, especially of significant medications prescribed in extended therapy. The most recent International Diabetes Federation (IDF) Diabetes Atlas (2025) indicates that 11.1%, equivalent to 1 in 9 of adults (aged 20-79) are affected by diabetes, with more than 40% being unaware of their condition. As chronic disease prevalence is rising in both developed and emerging economies, the need for cost-effective and scalable production is growing. Continuous manufacturing is meeting this need through consistent quality and quantity, such that patients are constantly receiving vital drugs without interruption.

Technological Innovations and Developments

Rapid technological advances are driving the adoption of continuous manufacturing, as pharma companies continue to infuse production processes with automation, artificial intelligence, digital twins, and predictive analytics. Sophisticated process control systems are facilitating real-time tracking, while machine learning algorithms are predicting potential drifts and maximizing efficiency. These advances are guaranteeing consistent quality of products, minimizing downtime, and reducing variability. Modular system architecture is providing flexibility, enabling buildings to fit in several drug sizes without extensive reorganization. Businesses are also making investments in digital platforms that are offering complete transparency throughout the production cycle with end-to-end traceability. Coupled with Industry 4.0 technologies, pharmaceutical production is becoming intelligent, agile, and quicker. These technologies are establishing continuous manufacturing as the pillar of future-proof pharmaceutical manufacture to help businesses stay competitive while fulfilling mounting world demand for affordable, dependable, and high-quality drugs. IMARC Group predicts that the global industry 4.0 market is expected to attain USD 570.5 Billion by 2033.

Regulatory Support and Encouragement

Regulatory bodies are increasingly encouraging continuous manufacturing through supportive guidelines, approvals, and frameworks. The U.S. Food and Drug Administration (FDA) is promoting innovation through regulatory adaptability, whereas the European Medicines Agency (EMA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) are converging towards global standards. These agencies are opening routes to swift uptake, and the companies are reciprocating by requesting approvals for continuous manufacturing techniques. By providing guidance on compliance, regulators are encouraging pharmaceutical companies to implement real-time quality monitoring, process analytical technology (PAT), and advanced control systems. This assistance is reducing uncertainty, speeding adoption, and establishing industry confidence. With increasing case studies being approved, the regulatory environment is strengthening confidence in continuous systems. This positive attitude is propelling adoption in small-molecule medications, biologics, and the personalized medicine space, making the industry globally gradually move toward extensive integration of continuous manufacturing. In 2024, the U.S. Food and Drug Administration (FDA) declared that it will be accepting applications between Jan. 2, 2024, and March 1, 2024, for the START pilot program to accelerate the development of rare disease therapeutics. Sponsor engagement in the pilot will be deemed completed once the development program achieves a major regulatory milestone, like commencing the pivotal clinical trial phase or reaching the stage before filing a marketing application (pre-Biologics License Application or pre-New Drug Application meeting stage), as agreed with the sponsor.

PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET GROWTH DRIVERS:

Cost Savings and Operational Benefits

The pharmaceutical industry is progressively embracing continuous manufacturing due to its enormous cost-benefit potential and operational benefits. Conventional batch production is demanding big spaces, heavy manpower, and long timelines, while continuous systems are decreasing energy usage, reducing raw material use, and eliminating waste. Through process simplification, companies are lowering the cost of production and realizing more output in fewer cycles. Continuous systems are also facilitating quicker scale-up, making it possible for manufacturers to transition faster from development to full-scale manufacture. These advantages are especially crucial with competition heating up and drug pricing pressures building around the world. Continuous manufacturing is also enabling smaller manufacturing footprints, which is reducing infrastructure costs. In keeping quality constant and minimizing failures during production, companies are preventing expensive delays and recalls. This efficiency of operation is becoming a primary motivator, as the sector is always looking to reconcile affordability, compliance, and patient access without sacrificing safety or quality.

Increased Demand for Biopharmaceuticals and Advanced Therapies

The pharma industry is gravitating toward continuous manufacturing increasingly as demand for biologics, biosimilars, and advanced therapies like cell and gene therapies is increasing at a fast pace. Legacy batch processes are no longer adequate to handle the multifaceted demands of such treatments, while continuous processes are facilitating greater consistency, efficiency, and scalability. Firms are adopting continuous upstream processes like perfusion bioreactors, and continuous downstream methods like chromatography, to guarantee product quality. These approaches are minimizing cycle times and facilitating quicker market introduction for critical therapies. The biopharmaceutical industry is also calling for precise control of variability, and continuous systems are answering this call by enabling real-time monitoring and sophisticated control mechanisms. With an escalating global demand for personalized and complex treatments, continuous manufacturing is taking a leading role in serving patient needs. This change is making sure that the pharmaceutical industry is reacting to one of its most significant growth drivers effectively.

Increasing Emphasis on Supply Chain Resilience

Continuous manufacturing is increasingly being embraced by pharmaceutical firms as they focus on supply chain resilience due to global upheavals. Batch production is typically based on long supply chains and centralized plants, which are susceptible to delays and shortages. In contrast, continuous manufacturing is facilitating localized, decentralized, and flexible models of production that are diminishing dependence on elaborate logistics chains. Firms are adopting smaller, modular plants near patients to provide timely access to drugs. This strategy is also lowering risks of supply disruptions in cases of emergencies and enhancing the capacity to deal with unexpected spikes in demand. Through increased supply chain flexibility, continuous manufacturing is enabling pharmaceutical firms to respond more rapidly to changes in the marketplace. The growing focus on resilience is propelling companies towards the adoption of continuous manufacturing, as companies can now see the strategic benefit of more secure, responsive, and sustainable production schemes.

GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING INDUSTRY SEGMENTATION:

Breakup by Therapeutics Type:

  • Large Molecules
  • Small Molecules

Small molecules dominate the pharmaceutical continuous manufacturing market

Continuous manufacturing enhances efficiency and consistency in small-molecule drugs. Vertex Pharmaceuticals introduced Suzetrigine, a small molecule drug manufactured using continuous processes, optimizing production efficiency and ensuring consistent quality for pain management.

Breakup by Formulation:

  • Solid Formulation
  • Liquid and Semi-solid Formulation

Solid formulation currently holds most of the pharmaceutical continuous manufacturing market demand

Solid formulations, such as capsules and tablets, excel in continuous manufacturing due to improved consistency and efficiency. For example, XenoPharma's tablet production ensures uniform quality and scalable output, which is acting as another significant growth-inducing factor.

Breakup by Application:

  • Final Drug Product Manufacturing
  • API Manufacturing

Final drug product manufacturing dominates the market

Final drug product manufacturing in continuous processes ensures efficient production with consistent quality and scalability, thereby reducing waste and enhancing overall process control. It also results in cost savings. This is bolstering the pharmaceutical continuous manufacturing market revenue.

Breakup by End User:

  • Pharmaceutical Companies
  • Contract Manufacturing Organizations
  • Others

Pharmaceutical companies hold most of the pharmaceutical continuous manufacturing market outlook

Pharmaceutical companies increasingly adopt continuous manufacturing to enhance efficiency, streamline production processes, and ensure consistent product quality. This is leading to faster and more cost-effective drug development.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America exhibits a clear dominance, accounting for the largest pharmaceutical continuous manufacturing market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

As per the pharmaceutical continuous manufacturing market research report, North America accounted for the largest share, driven by advanced drug delivery technologies. Moreover, regulatory bodies in the region are highly supportive of continuous manufacturing practices. The corporation with regulatory bodies encourages pharmaceutical companies to adopt continuous manufacturing solutions, thereby propelling the market growth. For instance, in May 2024, the U.S. Food and Drug Administration (FDA) introduced the START pilot program to catalyze the development of rare disease therapeutics.

COMPETITIVE LANDSCAPE:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market pharmaceutical continuous manufacturing companies have also been provided. Some of the key players in the market include:

  • Baker Perkins
  • Coperion GmbH (Hillenbrand Inc.)
  • Eli Lilly and Company
  • GEA Group Aktiengesellschaft
  • Glatt GmbH
  • Korsch AG
  • Novartis AG
  • Siemens
  • SK biotek
  • Thermo Fisher Scientific Inc.
  • Viatris Inc.

()

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the global pharmaceutical continuous manufacturing market?

2. What is the expected growth rate of the global pharmaceutical continuous manufacturing market during 2026-2034?

3. What are the key factors driving the global pharmaceutical continuous manufacturing market?

4. What has been the impact of COVID-19 on the global pharmaceutical continuous manufacturing market growth?

5. What is the breakup of the global pharmaceutical continuous manufacturing market based on the therapeutics type?

6. What is the breakup of the global pharmaceutical continuous manufacturing market based on formulation?

7. What is the breakup of the global pharmaceutical continuous manufacturing market based on the application?

8. What is the breakup of the global pharmaceutical continuous manufacturing market based on the end user?

9. What are the key regions in the global pharmaceutical continuous manufacturing market?

10. Who are the key players/companies in the global pharmaceutical continuous manufacturing market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pharmaceutical Continuous Manufacturing Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapeutics Type

  • 6.1 Large Molecules
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Small Molecules
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Formulation

  • 7.1 Solid Formulation
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Liquid and Semi-solid Formulation
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Final Drug Product Manufacturing
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 API Manufacturing
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Pharmaceutical Companies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Contract Manufacturing Organizations
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Baker Perkins
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 Coperion GmbH (Hillenbrand Inc.)
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Eli Lilly and Company
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 GEA Group Aktiengesellschaft
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Glatt GmbH
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
    • 15.3.6 Korsch AG
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 Novartis AG
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Siemens
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 SK biotek
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
    • 15.3.10 Thermo Fisher Scientific Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Viatris Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials

List of Figures

  • Figure 1: Global: Pharmaceutical Continuous Manufacturing Market: Major Drivers and Challenges
  • Figure 2: Global: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Pharmaceutical Continuous Manufacturing Market: Breakup by Therapeutics Type (in %), 2025
  • Figure 5: Global: Pharmaceutical Continuous Manufacturing Market: Breakup by Formulation (in %), 2025
  • Figure 6: Global: Pharmaceutical Continuous Manufacturing Market: Breakup by Application (in %), 2025
  • Figure 7: Global: Pharmaceutical Continuous Manufacturing Market: Breakup by End User (in %), 2025
  • Figure 8: Global: Pharmaceutical Continuous Manufacturing Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Pharmaceutical Continuous Manufacturing (Large Molecules) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Pharmaceutical Continuous Manufacturing (Large Molecules) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Pharmaceutical Continuous Manufacturing (Small Molecules) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Pharmaceutical Continuous Manufacturing (Small Molecules) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Pharmaceutical Continuous Manufacturing (Solid Formulation) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Pharmaceutical Continuous Manufacturing (Solid Formulation) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Pharmaceutical Continuous Manufacturing (Liquid and Semi-solid Formulation) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Pharmaceutical Continuous Manufacturing (Liquid and Semi-solid Formulation) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Pharmaceutical Continuous Manufacturing (Final Drug Product Manufacturing) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Pharmaceutical Continuous Manufacturing (Final Drug Product Manufacturing) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Pharmaceutical Continuous Manufacturing (API Manufacturing) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Pharmaceutical Continuous Manufacturing (API Manufacturing) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Pharmaceutical Continuous Manufacturing (Pharmaceutical Companies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Pharmaceutical Continuous Manufacturing (Pharmaceutical Companies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Pharmaceutical Continuous Manufacturing (Contract Manufacturing Organizations) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Pharmaceutical Continuous Manufacturing (Contract Manufacturing Organizations) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Pharmaceutical Continuous Manufacturing (Others) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Pharmaceutical Continuous Manufacturing (Others) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: North America: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: North America: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: United States: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: United States: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Canada: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Canada: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Asia-Pacific: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Asia-Pacific: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: China: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: China: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Japan: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Japan: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: India: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: India: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: South Korea: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: South Korea: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Australia: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Australia: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Indonesia: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Indonesia: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Others: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Others: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Europe: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Europe: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Germany: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Germany: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: France: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: France: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: United Kingdom: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: United Kingdom: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Italy: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Italy: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Spain: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Spain: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Russia: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Russia: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Others: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Others: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Latin America: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Latin America: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Brazil: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Brazil: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Mexico: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Mexico: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Others: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Others: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Middle East and Africa: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Middle East and Africa: Pharmaceutical Continuous Manufacturing Market: Breakup by Country (in %), 2025
  • Figure 75: Middle East and Africa: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Global: Pharmaceutical Continuous Manufacturing Industry: SWOT Analysis
  • Figure 77: Global: Pharmaceutical Continuous Manufacturing Industry: Value Chain Analysis
  • Figure 78: Global: Pharmaceutical Continuous Manufacturing Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pharmaceutical Continuous Manufacturing Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Pharmaceutical Continuous Manufacturing Market Forecast: Breakup by Therapeutics Type (in Million USD), 2026-2034
  • Table 3: Global: Pharmaceutical Continuous Manufacturing Market Forecast: Breakup by Formulation (in Million USD), 2026-2034
  • Table 4: Global: Pharmaceutical Continuous Manufacturing Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 5: Global: Pharmaceutical Continuous Manufacturing Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 6: Global: Pharmaceutical Continuous Manufacturing Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Pharmaceutical Continuous Manufacturing Market: Competitive Structure
  • Table 8: Global: Pharmaceutical Continuous Manufacturing Market: Key Players